Grand Pharmaceutical Group Limited (HK:0512) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Grand Pharmaceutical Group Limited reported a modest revenue increase of 1% year-over-year, reaching HK$6,047.24 million for the first half of 2024, with profits soaring by 51.4% to HK$1,557.95 million during the same period. The company has heavily invested in research and development, amounting to HK$1,480.00 million, while their nuclear medicine anti-tumor segment has experienced over 107% growth in revenue. Grand Pharmaceutical continues to focus on technological innovation and strategic global expansion to address unmet clinical needs and enhance treatment solutions.
For further insights into HK:0512 stock, check out TipRanks’ Stock Analysis page.